36. A method according to claim 28 wherein the graft is a bone graft.

37. A method according to claim 28 wherein the graft is a corneal transplant.

38. A method according to claim 28 wherein the graft is a hair transplant.

39. A method according to claim 28 wherein the graft is a cartilage graft.

40. A method according to claim 39 wherein the graft comprises cultured chondrocytes embedded in a carrier.

41. A method according to claim 28 wherein the active matrix enamel substance is enamel matrix, enamel matrix derivatives or enamel matrix proteins, or mixtures thereof.

42. A method according to claim 28 wherein the active matrix enamel substance is selected from the group consisting of enamelins, amelogenins, non-amelogenins, proline-rich amelogenins, amelins (ameloblastin, sheathlin), tuftelins, and derivatives thereof and mixtures thereof.

43. A method according to claim 28 wherein the active enamel substance has a molecular weight of up to about 120 kDa as determined by SDS Page electrophoresis.

44. A method according to claim 28 wherein the active enamel substance has a molecular weight of up to about 100 kDa as determined by SDS Page electrophoresis.

45. A method according to claim 28 wherein the active enamel substance has a molecular weight of up to about 60 kDa as determined by SDS Page electrophoresis.

46. A method according to claim 28 wherein the preparation of an active enamel substance contains a mixture of active enamel substances with different molecular weights.

47. A method according to claim 28 wherein the preparation of an active enamel substance comprises at least two substances selected from the group consisting of amelogenins, proline-rich non-amelogenins, tuftelin, tuft proteins, serum proteins, salivary proteins, amelin, ameloblastin, sheathlin, and derivatives thereof.

48. A method according to claim 28 wherein the active enamel substance has a molecular weight of between about 5,000 and about 25,000.

49. A method according to claim 28 wherein the major part of the active enamel substance has a molecular weight of about 20 kDa.

50. A method according to claim 28 wherein at least a part of the active enamel substance is in the form of aggregates or after application in vivo is capable of forming aggregates.

51. A method according to claim 28 wherein the aggregates have a particle size of from about 20 nm to about 1 μm.

52. A method according to claim 28 wherein the protein content of the active enamel substance in the preparation is in a range of from about 0.05% w/w to 100% w/w.

53. A method according to claim 28 wherein the protein content of the active enamel substance in the preparation is in a range of from about 30-90% w/w.

54. A method according to claim 28 wherein a pharmaceutical or cosmetic composition comprising an active enamel substance and a pharmaceutically acceptable excipient is administered to the mammal.